TPG Explores $5 Billion Sale of Healthcare Software Firm Lyric

Key Facts

1Private equity firm TPG is exploring options for a sale of healthcare software company Lyric.

2The potential deal could value Lyric at approximately $5 billion, including debt.

In a move reflecting the growing investment appetite for healthcare technology, private equity firm TPG is exploring options for a sale of Lyric, a healthcare software specialist. According to reports, TPG is working with investment banks to evaluate the potential divestiture of the company, in which it previously acquired a majority stake from UnitedHealth Group's Optum unit. The potential deal could value Lyric at approximately $5 billion, including debt, marking a significant exit for the global investment firm.

The decision follows TPG's restructuring and rebranding of the asset from ClaimsXten to Lyric, positioning it as a standalone, AI-driven platform for payment accuracy. TPG aims to capitalize on the firm's growth as a specialized technology asset focused on improving medical billing efficiency. Per market data, these discussions are currently in the early stages as acquisition rumors, and no final buyer has been officially confirmed at this time.

Based on current financial data, no immediate trading prices are available for Lyric as it remains a private entity under TPG, and price data for related instruments was unavailable as of September 9, 2026. Healthcare sector traders are monitoring for official announcements that could impact peer valuations. On the economic front, global markets are awaiting Eurozone retail sales and Canadian unemployment data later today, which may influence broader sentiment for private equity deal-making.